drugset / Trial / NCT00679432

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432

Phase 3 Completed 510 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare Budesonide MMX™ 6 mg and Budesonide MMX™ 9 mg tablets to placebo and to Asacol 6x 400 mg tablets over an 8-week treatment period to determine if Budesonide MMX™ is effective in the treatment of ulcerative colitis.

Timeline

Start
2008-06
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 6 mg Oral
Subject Budesonide Small molecule 9 mg Oral
Comparator Mesalamine Small molecule 2400 mg

Indications